A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease.
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2014
At a glance
- Drugs V 212 (Primary)
- Indications Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
- Sponsors Merck Sharp & Dohme
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2012 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 30 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.